Ventyx Biosciences Stockholders Approve Eli Lilly Merger Agreement

summarizeSummary

Ventyx Biosciences, Inc. announced that its stockholders have approved the Agreement and Plan of Merger with Eli Lilly and Company, advancing the acquisition process.

check_boxKey Events

• Merger Agreement Adopted

  Stockholders voted to adopt the Agreement and Plan of Merger with Eli Lilly and Company, with 44,176,785 shares voting FOR the proposal.

• Executive Compensation Approved

  Stockholders also approved, on a non-binding advisory basis, the compensation for named executive officers in connection with the merger.

• Special Meeting Held

  A special meeting of stockholders was held virtually on March 3, 2026, to consider and vote on the merger-related proposals.

auto_awesomeAnalysis

This 8-K filing confirms a critical milestone in the acquisition of Ventyx Biosciences by Eli Lilly and Company. Shareholder approval of the merger agreement significantly de-risks the transaction and moves it closer to completion. While the merger was previously announced, this vote provides the necessary shareholder consent, indicating strong support for the deal. Investors should now anticipate the remaining regulatory approvals and closing conditions.